Raymond James Financial Inc. Takes Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Raymond James Financial Inc. bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 92,904 shares of the company’s stock, valued at approximately $3,450,000. Raymond James Financial Inc. owned 0.19% of Amphastar Pharmaceuticals as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. grew its stake in Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after buying an additional 398 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after purchasing an additional 493 shares during the last quarter. KBC Group NV increased its stake in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after purchasing an additional 650 shares during the period. Sanctuary Advisors LLC lifted its holdings in Amphastar Pharmaceuticals by 8.5% during the 3rd quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock worth $466,000 after purchasing an additional 801 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Amphastar Pharmaceuticals by 8.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,195 shares of the company’s stock valued at $379,000 after purchasing an additional 833 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ AMPH opened at $28.50 on Friday. The company has a 50 day simple moving average of $31.22 and a 200 day simple moving average of $40.08. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a 1 year low of $25.89 and a 1 year high of $53.96. The firm has a market cap of $1.36 billion, a PE ratio of 9.50, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.